ACM-Pivotal celebrates seven years of clinical trials in Russia

ACM-Pivotal is celebrating its seventh anniversary of providing central lab services for contract research organisations conducting clinical trials and companies in the pharmaceutical and biotechnology industries

The company's first Russian study was conducted in 2000 and over the past seven years has maintained a successful track record by mastering local requirements and gaining extensive experience within the region.

Expansion of clinical trials into central and eastern Europe began over a decade ago, starting with countries such as Poland and the Czech Republic and extending now into countries such as the Ukraine, Lithuania, Estonia, Latvia, Serbia & Montenegro, Bulgaria, Georgia and Romania.

ACM-Pivotal routinely supports clinical trials in all of these countries covering a wide range of therapeutic areas, such as oncology, cardiovascular and respiratory diseases, dermatology, diabetes and rheumatoid arthritis.

According to managing director Jerry Boxall key reasons that make Russia and eastern Europe such an attractive markets for clinical trial is the ability to recruit patients and compliance linked to high quality investigator sites.

Investigators and patients in Russia and other countries of the region are highly motivated to participate in clinical trials,. he said. Patients are looking for the best medical care available from highly-qualified physicians, whose compliance with protocols and procedures is often of a higher standard than that seen in Western countries..

Patient recruitment is seldom a problem in this region, and in trials where there is competitive recruitment, we confidently expect that Russia will contribute more than it's share of patients for a trial..

While there is a growing pursuit of emerging markets such as India and China, ACM-Pivotal anticipates that eastern Europe will remain a significant region in the conduct of clinical trials in the foreseeable future.

ACM-Pivotal recently announced significant expansion to accommodate its current and anticipated growth of the business on a global basis. Currently, the organisation's global operations extend to more than 60 countries, including the Americas, Europe, including eastern Europe and Russia, Australia, Asia, Israel and South Africa - with all tests conducted and managed from central lab facilities.

Last year, the organisation expanded its capabilities to conduct trials in India.